6 completed. 6 Phase 3, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 6 | Completed 6 |
| Phase 2 | 1 | Completed 1 |
Follow Hemophilia: new trials by email Literature Review of Hemophilia trials Research Report on Hemophilia
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Fitusiran Prophylaxis in Male Pediatric Subjects Aged 1 to Less Than 12 Years With Hemophilia A or B Fitusiran - Hemophilia | Phase 2 / Phase 3 | Completed | Genzyme, a Sanofi Company | 32 | 2020-01-28 | 2026-09-28 |
| Long-term Safety and Efficacy Study of Fitusiran in Patients With Hemophilia A or B, With or Without Inhibitory Antibodies to Factor VIII or IX Fitusiran - Hemophilia | Phase 3 | Completed | Genzyme, a Sanofi Company | 281 | 2019-01-09 | 2026-09-30 |
| A Study of Fitusiran in Severe Hemophilia A and B Patients Previously Receiving Factor or Bypassing Agent Prophylaxis Fitusiran, BPA prophylaxis, Factor (FVIII or FIX) prophylaxis - Hemophilia | Phase 3 | Completed | Genzyme, a Sanofi Company | 80 | 2018-07-25 | 2023-02-06 |
| LR769 in Congenital Hemophilia Patients With Inhibitors Undergoing Elective Surgery or Invasive Procedures Coagulation Factor VIIa (Recombinant) - Hemophilia | Phase 3 | Completed | Laboratoire français de Fractionnement et de Biotechnologies | 12 | 2016-08-25 | 2022-02-25 |
| Prospective Biomarkers of Bone Metabolism in Hemophilia A Advate - Hemophilia, Bone Disease | Phase 3 | Completed | Oregon Health and Science University | 16 | 2014-12-01 | 2020-04-01 |
| BAY14-2222 Continuous Infusion in Surgeries Kogenate (BAY14-2222) - Hemophilia | Phase 3 | Completed | Bayer | 15 | 2004-07-01 | 2010-04-13 |
Hemophilia A (6) · Bone Diseases (1)
Blood Coagulation Disorders (6) · Blood Coagulation Disorders, Inherited (6) · Coagulation Protein Disorders (6) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (6) · Genetic Diseases, Inborn (6) · Hematologic Diseases (6) · Hemic and Lymphatic Diseases (6) · Hemorrhagic Disorders (6) · Musculoskeletal Diseases (1)
fitusiran (3) · BAY 14-2222 (1) · F8 protein, human (1) · Factor VII (1) · Factor VIII (1)
Genzyme, a Sanofi Company (3) · Bayer (1) · Laboratoire français de Fractionnement et de Biotechnologies (1) · Oregon Health and Science University (1)
United States (5) · Israel (3) · Italy (3) · Turkey (Türkiye) (3) · Ukraine (3) · Australia (2) · Canada (2) · China (2) · Denmark (2) · France (2) · India (2) · Ireland (2) · Japan (2) · Malaysia (2) · Mexico (2)
Jason Taylor, MD, PhD (1) · Miguel Escobar, MD (1)
2016 (1), 2018 (1), 2019 (1), 2023 (1)